Background: In recent investigations addressing neurodegenerative diseases, especially multiple sclerosis (MS), the roles of brain-derived neurotrophic factor (BDNF) and interleukin-6 (IL-6) have been examined. Methods: Forty-five relapsing-remitting MS (RRMS) patients, including 32 IFN-β-treated and 13 newly identified untreated cases as well as 45 sex- and age-matched healthy controls, were recruited in the study. Plasma levels of BDNF and IL-6 were assessed using the ELISA method. Data were analyzed by SPSS (ver.21). Results: There were significant differences between the case and healthy control groups in terms of the plasma levels of BDNF (p value = 0.044) and IL-6 (p value #x3c;0.001). Besides, the treatment with IFN-β had no significant impact on the level of BDNF or IL-6 in RRMS patients as compared to healthy controls (p value = 0.716 and 0.623 for BDNF and IL-6, respectively). Furthermore, the increase in the plasma levels of BDNF and IL-6 indicated a direct correlation in the case group (r = 0.508, p value = 0.008). In detail, following the classification of the case group into 2 subgroups of IFN-β-treated and untreated patients, a direct positive correlation was observed between the plasma levels of BDNF and IL-6 in IFN-β-treated patients (r = 0.495, p value = 0.026). Conclusion: The IFN-β treatment seems not to be effective for upregulating BDNF and IL-6 in RRMS patients.
Neuroimmunomodulation

中文翻译：

---

IFN-β治疗对复发缓解型多发性硬化患者血浆BDNF和IL-6水平的影响

背景：在最近针对神经退行性疾病，尤其是多发性硬化症 (MS) 的研究中，已经检查了脑源性神经营养因子 (BDNF) 和白细胞介素 6 (IL-6) 的作用。方法：本研究招募了 45 名复发缓解型 MS (RRMS) 患者，包括 32 名接受 IFN-β 治疗的病例和 13 名新发现的未治疗病例以及 45 名性别和年龄匹配的健康对照。使用ELISA方法评估BDNF和IL-6的血浆水平。数据通过SPSS（ver.21）进行分析。结果：病例组与健康对照组血浆BDNF（ p值=0.044）和IL-6（ p值 #x3c;0.001)。此外，与健康对照相比，用 IFN-β 治疗对 RRMS 患者的 BDNF 或 IL-6 水平没有显着影响（BDNF 和 IL-6 的p值分别为 0.716 和 0.623）。此外，BDNF 和 IL-6 血浆水平的增加表明病例组中存在直接相关性（r = 0.508，p值 = 0.008）。具体而言，将病例组分为 IFN-β 治疗和未治疗患者 2 个亚组后，观察到 IFN-β 治疗患者血浆 BDNF 和 IL-6 水平呈直接正相关（r = 0.495 ，p值 = 0.026）。结论：IFN-β 治疗似乎不能有效上调 RRMS 患者的 BDNF 和 IL-6。
神经免疫调节